Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 105mg/1.17mL (single-use prefilled syringe)
- Syringe is not made with natural rubber latex
Osteoporosis
Indicated for osteoporosis treatment in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture; also indicated for patients in whom other available osteoporosis therapy has failed or who are intolerant of other available osteoporosis therapy
210 mg SC qMonth x 12 months
Adequately supplement patient with calcium and vitamin D during treatment
Dosage Modifications
Renal impairment
- No dose adjustment required
- Severe renal impairment (eGFR 15-29 mL/min/1.73 m²) or receiving dialysis: Greater risk of developing hypocalcemia; monitor calcium concentrations and adequately supplement calcium and vitamin D in these patients
Dosing Considerations
Limitations of use
- Anabolic effect wanes after 12 monthly doses; therefore, duration of use should be limited to 12 monthly doses
- If osteoporosis therapy remains warranted, consider continued treatment with an antiresorptive agent
Safety and efficacy not established
Adverse Effects
>10%
Arthralgia (8.1-13.1%)
1-10%
Headache (5.2-6.6%)
Hypersensitivity (6.5%)
Injection site reactions (4.9%)
Muscle spasms (3.4-4.6%)
Asthenia (2.3-2.5%)
Peripheral edema (1.7-2.4%)
Neck pain (1.7-2.2%)
Insomnia (1.7-2%)
Paresthesia (1.4-2%)
<1%
Hypocalcemia (0.2%)
Major adverse cardiac event (MACE)
Study 1
- Myocardial infarction (MI): 0.3% (0.2% placebo)
- Stroke: 0.2% (0.3% placebo)
- Cardiovascular (CV) death 0.5% (0.4% placebo)
Study 2
- MI: 0.8% (0.2% alendronate)
- Stroke: 0.6% (0.3% alendronate)
- CV death 0.8% (0.6% alendronate)
- Positively adjudicated MACE: 2% (1.1% alendronate); hazard ratio 1.87
Frequency Not Defined
Osteonecrosis of the jaw (ONJ)
Atypical femoral fracture
Warnings
Black Box Warnings
May increase the risk of MI, stroke, and CV death
Do not initiate in patients who have had an MI or stroke within the preceding year
Consider whether the benefits outweigh the risks in patients with other CV risk factors
If a patient experiences an MI or stroke during therapy, discontinue drug immediately
Contraindications
Hypocalcemia; preexisting hypocalcemia must be corrected before initiating
Systemic hypersensitivity (eg, angioedema, erythema multiforme, urticaria)
Cautions
A higher rate of MACE, a composite endpoint of CV death, nonfatal MI, and nonfatal stroke was observed in a randomized controlled trial in postmenopausal women treated with romosozumab compared with alendronate; monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur
Hypersensitivity reactions reported, including angioedema, erythema multiforme, dermatitis, rash, and urticaria; discontinue drug and initiate appropriate treatment if anaphylaxis or other clinically significant allergic reaction occurs
Hypocalcemia reported; correct hypocalcemia before initiating; monitor for signs and symptoms of hypocalcemia; ensure adequate supplementation with calcium and vitamin D during therapy
Atypical subtrochanteric and diaphyseal femoral fractures
- Atypical low-energy or low-trauma femoral shaft fractures reported; many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs
- Femoral fractures: During treatment, patients should be advised to report new or unusual thigh, hip, or groin pain; any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture
- Patient presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb; interruption of therapy should be considered based on benefit-risk assessment
Osteonecrosis of the jaw
- ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing and has been reported in patients receiving romosozumab
- Perform routine oral examination before initiating treatment; concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase ONJ risk
- Other risk factors include cancer, radiotherapy, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy
- For patients requiring invasive dental procedures, clinical judgment of the treating physician and/or oral surgeon should guide the management plan
- Discontinuation should be considered based on benefit-risk assessment
Pregnancy
Pregnancy
Not indicated for use in women of reproductive potential
In animal reproduction studies, weekly administration to pregnant rats during the period of organogenesis at exposures >32 times the clinical exposure produced skeletal abnormalities in the offspring
Administration to rats prior to mating and through to the end of lactation produced minimal-to-slight decreases in femoral bone mineral density and/or cortical circumferences in the offspring at 1.5-56 times the expected exposure in humans
Lactation
Not indicated for use in women of reproductive potential
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Monoclonal antibody (IgG2) that binds sclerostin, a regulatory factor in bone metabolism
Sclerostin inhibition increases bone formation and, to a lesser extent, decreases bone resorption
Animal studies showed that romosozumab stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity, resulting in increases in trabecular and cortical bone mass and improvements in bone structure and strength
Absorption
Peak plasma time: 5 days
Peak plasma concentration: 22.2 mcg/mL
AUC: 389 mcg·day/mL
Steady-state achieved by 3 months following monthly injections
Development of antibodies to romosozumab led to decreased mean concentrations up to 22%
Distribution
Vd: ~3.92 L
Metabolism
Not characterized; IgG2 expected to be degraded into small peptides and amino acids via catabolic pathways similar to endogenous IgG
Elimination
Half-life: 12.8 days
Clearance: 0.38 mL/hr/kg
Administration
SC Preparation
Remove 2 syringes from carton and visually inspect for particles and discoloration; solution should appear clear to opalescent, colorless to light yellow
Do not use if solution is cloudy, discolored, or contains particles
Do not use if syringe is cracked or broken, gray needle cap is missing or not securely attached, or passed the expiration date
Always hold syringe by the barrel to remove from the tray; do not grasp by plunger rod or gray needle cap
Do not remove gray needle cap until ready to inject
Allow to sit at room temperature for at least 30 minutes before injecting; do not warm in any other way
Clean injection site with alcohol wipes; let skin dry
Choose different injection site for each injection; if same injection location, do not inject near previous injection site
Do not inject in areas where skin is tender, bruised, red, or hard; avoid scars or stretch marks
SC Administration
Administered SC once monthly by healthcare professional
Total dose of 210 mg SC requires 2 separate 105-mg prefilled syringes (and 2 separate SC injections)
Inject two 105-mg prefilled syringes, one after the other, in abdomen (except for 2-inch area around navel), thigh, or outer area of upper arm
Missed dose: Administer as soon as possible; thereafter, schedule doses once monthly from the date of the last dose
Storage
Refrigerate at 2-8°C (36-46°F) in the original carton to protect from light
Do not freeze
Do not shake
If removed from refrigerator, can be kept at room temperature up to 25°C (77°F) in original carton and must be used within 30 days; if not used within 30 days, discard
Do not expose to temperatures >25°C (77°F)
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.